An evaluation of the drug-drug interaction between proton-pump inhibitors and EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients.

被引：0
|
作者：
Chan, Alexandre
Chen, Bingrong
Ng, Raymond [2 ]
Yong, Wei-Peng [1 ]
Ko, Yu
机构：
[1] Natl Univ Singapore, Inst Canc, Singapore 117548, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：E221 / E222
页数：2
相关论文
共 50 条
  • [1] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [2] Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
    Lau, Yvonne Y.
    Gu, Wen
    Lin, Tiffany
    Viraswami-Appanna, Kalyanee
    Cai, Can
    Scott, Jeffrey W.
    Shi, Michael
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1119 - 1128
  • [3] Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
    Occhipinti, Mario
    Brambilla, Marta
    Galli, Giulia
    Manglaviti, Sara
    Giammaruco, Maristella
    Prelaj, Arsela
    Ferrara, Roberto
    De Toma, Alessandro
    Proto, Claudia
    Beninato, Teresa
    Zattarin, Emma
    Lo Russo, Giuseppe
    Gelibter, Alain Jonathan
    Simmaco, Maurizio
    Preissner, Robert
    Garassino, Marina Chiara
    De Braud, Filippo
    Marchetti, Paolo
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (05):
  • [4] The drug-drug interaction between proton pump inhibitors and clopidogrel
    Lau, Wei C.
    Gurbel, Paul A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (07) : 699 - 700
  • [5] Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
    Norgard, Nicholas B.
    Mathews, Kathryn D.
    Wall, Geoffrey C.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) : 1266 - 1274
  • [6] Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma
    Libiad, Youssef
    Boutayeb, Saber
    Chaibi, Aicha
    BULLETIN DU CANCER, 2022, 109 (03) : 358 - 381
  • [7] In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors
    Ollier, Edouard
    Hodin, Sophie
    Basset, Thierry
    Accassat, Sandrine
    Bertoletti, Laurent
    Mismetti, Patrick
    Delavenne, Xavier
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (06) : 604 - 614
  • [8] Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.
    Okunrobo, M.
    Walker, D.
    Dumais, K.
    Powery, H.
    Izquierdo, P.
    Raez, L. E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S634 - S634
  • [9] The potential drug-drug interaction between proton pump inhibitors and warfarin
    Henriksen, Daniel Pilsgaard
    Stage, Tore Bjerregaard
    Hansen, Morten Rix
    Rasmussen, Lotte
    Damkier, Per
    Pottegard, Anton
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (12) : 1337 - 1340
  • [10] Comment: Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
    Chua, Doson
    Lo, Angelo
    Day, Jane
    Drummond, Isla
    McCollum, Robert
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (01) : 225 - 226
12345